Topical amorolfine for 15 months combined with 12 weeks of oral terbinafine, a cost-effective treatment for onychomycosis[This mater]
Objective This open randomized study examined the efficacy of a combination of oral terbinafine and topical amorolfine in the treatment of severe dermatophyte toenail onychomycosis with matrix area involvement. Patients/Methods A total of 147 patients were randomized to one of three treatment groups...
Ausführliche Beschreibung
Gespeichert in:
| Autor*in: |
Baran, R. [verfasserIn] |
|---|
| Format: |
E-Artikel |
|---|
| Erschienen: |
Oxford, UK: Blackwell Science Ltd ; 2001 |
|---|
| Schlagwörter: |
|---|
| Umfang: |
Online-Ressource |
|---|
| Reproduktion: |
2008 ; Blackwell Publishing Journal Backfiles 1879-2005 |
|---|---|
| Übergeordnetes Werk: |
In: British journal of dermatology - Oxford : Wiley-Blackwell, 1892, 145(2001), 60, Seite 0 |
| Übergeordnetes Werk: |
volume:145 ; year:2001 ; number:60 ; pages:0 |
| Links: |
|---|
| DOI / URN: |
10.1111/j.1365-2133.2001.00045.x |
|---|
| Katalog-ID: |
NLEJ242126944 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLEJ242126944 | ||
| 003 | DE-627 | ||
| 005 | 20230505191003.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 120427s2001 xx |||||o 00| ||und c | ||
| 024 | 7 | |a 10.1111/j.1365-2133.2001.00045.x |2 doi | |
| 035 | |a (DE-627)NLEJ242126944 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 100 | 1 | |a Baran, R. |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Topical amorolfine for 15 months combined with 12 weeks of oral terbinafine, a cost-effective treatment for onychomycosis[This mater] |
| 264 | 1 | |a Oxford, UK |b Blackwell Science Ltd |c 2001 | |
| 300 | |a Online-Ressource | ||
| 336 | |a nicht spezifiziert |b zzz |2 rdacontent | ||
| 337 | |a nicht spezifiziert |b z |2 rdamedia | ||
| 338 | |a nicht spezifiziert |b zu |2 rdacarrier | ||
| 520 | |a Objective This open randomized study examined the efficacy of a combination of oral terbinafine and topical amorolfine in the treatment of severe dermatophyte toenail onychomycosis with matrix area involvement. Patients/Methods A total of 147 patients were randomized to one of three treatment groups: 15 months of once-weekly topical amorolfine lacquer in combination with 6 weeks (Group AT6) or 12 weeks (Group AT12) of oral terbinafine, 250 mg once daily; or terbinafine monotherapy for 12 weeks (Group T12). Patients were followed for a total of 18 months. The primary efficacy variable was the result of mycological examination after 3 months of therapy; secondary efficacy variables were mycological and clinical examination at 3-monthly intervals, with an additional clinical evaluation at 18 months. Safety and tolerance were also assessed. Results Negative mycological results, assessed at 3 months, were recorded for 14 of 40 patients (35%) in Group AT6, 11 of 44 (27·5%) in Group AT12 and 7 of 41 (17·1%) in Group T12. At 18 months, the global response (mycological and clinical cure) was seen in 22 of 50 patients (44%), 34 of 47 (72·3%) and 18 of 48 (37·5%) in the AT6, AT12 and T12 groups, respectively. Conclusions These results suggest that a combination therapy regime with oral and systemic treatment is superior in efficacy to monotherapy with a systemic drug alone in the treatment of severe onychomycosis. In addition, the cost per cure ratio was better in the combination groups. | ||
| 533 | |d 2008 |f Blackwell Publishing Journal Backfiles 1879-2005 |7 |2008|||||||||| | ||
| 650 | 4 | |a onychomycosis | |
| 773 | 0 | 8 | |i In |t British journal of dermatology |d Oxford : Wiley-Blackwell, 1892 |g 145(2001), 60, Seite 0 |h Online-Ressource |w (DE-627)NLEJ24392786X |w (DE-600)2004086-6 |x 1365-2133 |7 nnns |
| 773 | 1 | 8 | |g volume:145 |g year:2001 |g number:60 |g pages:0 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1111/j.1365-2133.2001.00045.x |q text/html |x Verlag |z Deutschlandweit zugänglich |3 Volltext |
| 912 | |a GBV_USEFLAG_U | ||
| 912 | |a ZDB-1-DJB | ||
| 912 | |a GBV_NL_ARTICLE | ||
| 951 | |a AR | ||
| 952 | |d 145 |j 2001 |e 60 |h 0 | ||
| author_variant |
r b rb |
|---|---|
| matchkey_str |
article:13652133:2001----::oiaaoofnfr5otsobndih2ekooatriaiecsefcieram |
| hierarchy_sort_str |
2001 |
| publishDate |
2001 |
| allfields |
10.1111/j.1365-2133.2001.00045.x doi (DE-627)NLEJ242126944 DE-627 ger DE-627 rakwb Baran, R. verfasserin aut Topical amorolfine for 15 months combined with 12 weeks of oral terbinafine, a cost-effective treatment for onychomycosis[This mater] Oxford, UK Blackwell Science Ltd 2001 Online-Ressource nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Objective This open randomized study examined the efficacy of a combination of oral terbinafine and topical amorolfine in the treatment of severe dermatophyte toenail onychomycosis with matrix area involvement. Patients/Methods A total of 147 patients were randomized to one of three treatment groups: 15 months of once-weekly topical amorolfine lacquer in combination with 6 weeks (Group AT6) or 12 weeks (Group AT12) of oral terbinafine, 250 mg once daily; or terbinafine monotherapy for 12 weeks (Group T12). Patients were followed for a total of 18 months. The primary efficacy variable was the result of mycological examination after 3 months of therapy; secondary efficacy variables were mycological and clinical examination at 3-monthly intervals, with an additional clinical evaluation at 18 months. Safety and tolerance were also assessed. Results Negative mycological results, assessed at 3 months, were recorded for 14 of 40 patients (35%) in Group AT6, 11 of 44 (27·5%) in Group AT12 and 7 of 41 (17·1%) in Group T12. At 18 months, the global response (mycological and clinical cure) was seen in 22 of 50 patients (44%), 34 of 47 (72·3%) and 18 of 48 (37·5%) in the AT6, AT12 and T12 groups, respectively. Conclusions These results suggest that a combination therapy regime with oral and systemic treatment is superior in efficacy to monotherapy with a systemic drug alone in the treatment of severe onychomycosis. In addition, the cost per cure ratio was better in the combination groups. 2008 Blackwell Publishing Journal Backfiles 1879-2005 |2008|||||||||| onychomycosis In British journal of dermatology Oxford : Wiley-Blackwell, 1892 145(2001), 60, Seite 0 Online-Ressource (DE-627)NLEJ24392786X (DE-600)2004086-6 1365-2133 nnns volume:145 year:2001 number:60 pages:0 http://dx.doi.org/10.1111/j.1365-2133.2001.00045.x text/html Verlag Deutschlandweit zugänglich Volltext GBV_USEFLAG_U ZDB-1-DJB GBV_NL_ARTICLE AR 145 2001 60 0 |
| spelling |
10.1111/j.1365-2133.2001.00045.x doi (DE-627)NLEJ242126944 DE-627 ger DE-627 rakwb Baran, R. verfasserin aut Topical amorolfine for 15 months combined with 12 weeks of oral terbinafine, a cost-effective treatment for onychomycosis[This mater] Oxford, UK Blackwell Science Ltd 2001 Online-Ressource nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Objective This open randomized study examined the efficacy of a combination of oral terbinafine and topical amorolfine in the treatment of severe dermatophyte toenail onychomycosis with matrix area involvement. Patients/Methods A total of 147 patients were randomized to one of three treatment groups: 15 months of once-weekly topical amorolfine lacquer in combination with 6 weeks (Group AT6) or 12 weeks (Group AT12) of oral terbinafine, 250 mg once daily; or terbinafine monotherapy for 12 weeks (Group T12). Patients were followed for a total of 18 months. The primary efficacy variable was the result of mycological examination after 3 months of therapy; secondary efficacy variables were mycological and clinical examination at 3-monthly intervals, with an additional clinical evaluation at 18 months. Safety and tolerance were also assessed. Results Negative mycological results, assessed at 3 months, were recorded for 14 of 40 patients (35%) in Group AT6, 11 of 44 (27·5%) in Group AT12 and 7 of 41 (17·1%) in Group T12. At 18 months, the global response (mycological and clinical cure) was seen in 22 of 50 patients (44%), 34 of 47 (72·3%) and 18 of 48 (37·5%) in the AT6, AT12 and T12 groups, respectively. Conclusions These results suggest that a combination therapy regime with oral and systemic treatment is superior in efficacy to monotherapy with a systemic drug alone in the treatment of severe onychomycosis. In addition, the cost per cure ratio was better in the combination groups. 2008 Blackwell Publishing Journal Backfiles 1879-2005 |2008|||||||||| onychomycosis In British journal of dermatology Oxford : Wiley-Blackwell, 1892 145(2001), 60, Seite 0 Online-Ressource (DE-627)NLEJ24392786X (DE-600)2004086-6 1365-2133 nnns volume:145 year:2001 number:60 pages:0 http://dx.doi.org/10.1111/j.1365-2133.2001.00045.x text/html Verlag Deutschlandweit zugänglich Volltext GBV_USEFLAG_U ZDB-1-DJB GBV_NL_ARTICLE AR 145 2001 60 0 |
| allfields_unstemmed |
10.1111/j.1365-2133.2001.00045.x doi (DE-627)NLEJ242126944 DE-627 ger DE-627 rakwb Baran, R. verfasserin aut Topical amorolfine for 15 months combined with 12 weeks of oral terbinafine, a cost-effective treatment for onychomycosis[This mater] Oxford, UK Blackwell Science Ltd 2001 Online-Ressource nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Objective This open randomized study examined the efficacy of a combination of oral terbinafine and topical amorolfine in the treatment of severe dermatophyte toenail onychomycosis with matrix area involvement. Patients/Methods A total of 147 patients were randomized to one of three treatment groups: 15 months of once-weekly topical amorolfine lacquer in combination with 6 weeks (Group AT6) or 12 weeks (Group AT12) of oral terbinafine, 250 mg once daily; or terbinafine monotherapy for 12 weeks (Group T12). Patients were followed for a total of 18 months. The primary efficacy variable was the result of mycological examination after 3 months of therapy; secondary efficacy variables were mycological and clinical examination at 3-monthly intervals, with an additional clinical evaluation at 18 months. Safety and tolerance were also assessed. Results Negative mycological results, assessed at 3 months, were recorded for 14 of 40 patients (35%) in Group AT6, 11 of 44 (27·5%) in Group AT12 and 7 of 41 (17·1%) in Group T12. At 18 months, the global response (mycological and clinical cure) was seen in 22 of 50 patients (44%), 34 of 47 (72·3%) and 18 of 48 (37·5%) in the AT6, AT12 and T12 groups, respectively. Conclusions These results suggest that a combination therapy regime with oral and systemic treatment is superior in efficacy to monotherapy with a systemic drug alone in the treatment of severe onychomycosis. In addition, the cost per cure ratio was better in the combination groups. 2008 Blackwell Publishing Journal Backfiles 1879-2005 |2008|||||||||| onychomycosis In British journal of dermatology Oxford : Wiley-Blackwell, 1892 145(2001), 60, Seite 0 Online-Ressource (DE-627)NLEJ24392786X (DE-600)2004086-6 1365-2133 nnns volume:145 year:2001 number:60 pages:0 http://dx.doi.org/10.1111/j.1365-2133.2001.00045.x text/html Verlag Deutschlandweit zugänglich Volltext GBV_USEFLAG_U ZDB-1-DJB GBV_NL_ARTICLE AR 145 2001 60 0 |
| allfieldsGer |
10.1111/j.1365-2133.2001.00045.x doi (DE-627)NLEJ242126944 DE-627 ger DE-627 rakwb Baran, R. verfasserin aut Topical amorolfine for 15 months combined with 12 weeks of oral terbinafine, a cost-effective treatment for onychomycosis[This mater] Oxford, UK Blackwell Science Ltd 2001 Online-Ressource nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Objective This open randomized study examined the efficacy of a combination of oral terbinafine and topical amorolfine in the treatment of severe dermatophyte toenail onychomycosis with matrix area involvement. Patients/Methods A total of 147 patients were randomized to one of three treatment groups: 15 months of once-weekly topical amorolfine lacquer in combination with 6 weeks (Group AT6) or 12 weeks (Group AT12) of oral terbinafine, 250 mg once daily; or terbinafine monotherapy for 12 weeks (Group T12). Patients were followed for a total of 18 months. The primary efficacy variable was the result of mycological examination after 3 months of therapy; secondary efficacy variables were mycological and clinical examination at 3-monthly intervals, with an additional clinical evaluation at 18 months. Safety and tolerance were also assessed. Results Negative mycological results, assessed at 3 months, were recorded for 14 of 40 patients (35%) in Group AT6, 11 of 44 (27·5%) in Group AT12 and 7 of 41 (17·1%) in Group T12. At 18 months, the global response (mycological and clinical cure) was seen in 22 of 50 patients (44%), 34 of 47 (72·3%) and 18 of 48 (37·5%) in the AT6, AT12 and T12 groups, respectively. Conclusions These results suggest that a combination therapy regime with oral and systemic treatment is superior in efficacy to monotherapy with a systemic drug alone in the treatment of severe onychomycosis. In addition, the cost per cure ratio was better in the combination groups. 2008 Blackwell Publishing Journal Backfiles 1879-2005 |2008|||||||||| onychomycosis In British journal of dermatology Oxford : Wiley-Blackwell, 1892 145(2001), 60, Seite 0 Online-Ressource (DE-627)NLEJ24392786X (DE-600)2004086-6 1365-2133 nnns volume:145 year:2001 number:60 pages:0 http://dx.doi.org/10.1111/j.1365-2133.2001.00045.x text/html Verlag Deutschlandweit zugänglich Volltext GBV_USEFLAG_U ZDB-1-DJB GBV_NL_ARTICLE AR 145 2001 60 0 |
| allfieldsSound |
10.1111/j.1365-2133.2001.00045.x doi (DE-627)NLEJ242126944 DE-627 ger DE-627 rakwb Baran, R. verfasserin aut Topical amorolfine for 15 months combined with 12 weeks of oral terbinafine, a cost-effective treatment for onychomycosis[This mater] Oxford, UK Blackwell Science Ltd 2001 Online-Ressource nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Objective This open randomized study examined the efficacy of a combination of oral terbinafine and topical amorolfine in the treatment of severe dermatophyte toenail onychomycosis with matrix area involvement. Patients/Methods A total of 147 patients were randomized to one of three treatment groups: 15 months of once-weekly topical amorolfine lacquer in combination with 6 weeks (Group AT6) or 12 weeks (Group AT12) of oral terbinafine, 250 mg once daily; or terbinafine monotherapy for 12 weeks (Group T12). Patients were followed for a total of 18 months. The primary efficacy variable was the result of mycological examination after 3 months of therapy; secondary efficacy variables were mycological and clinical examination at 3-monthly intervals, with an additional clinical evaluation at 18 months. Safety and tolerance were also assessed. Results Negative mycological results, assessed at 3 months, were recorded for 14 of 40 patients (35%) in Group AT6, 11 of 44 (27·5%) in Group AT12 and 7 of 41 (17·1%) in Group T12. At 18 months, the global response (mycological and clinical cure) was seen in 22 of 50 patients (44%), 34 of 47 (72·3%) and 18 of 48 (37·5%) in the AT6, AT12 and T12 groups, respectively. Conclusions These results suggest that a combination therapy regime with oral and systemic treatment is superior in efficacy to monotherapy with a systemic drug alone in the treatment of severe onychomycosis. In addition, the cost per cure ratio was better in the combination groups. 2008 Blackwell Publishing Journal Backfiles 1879-2005 |2008|||||||||| onychomycosis In British journal of dermatology Oxford : Wiley-Blackwell, 1892 145(2001), 60, Seite 0 Online-Ressource (DE-627)NLEJ24392786X (DE-600)2004086-6 1365-2133 nnns volume:145 year:2001 number:60 pages:0 http://dx.doi.org/10.1111/j.1365-2133.2001.00045.x text/html Verlag Deutschlandweit zugänglich Volltext GBV_USEFLAG_U ZDB-1-DJB GBV_NL_ARTICLE AR 145 2001 60 0 |
| source |
In British journal of dermatology 145(2001), 60, Seite 0 volume:145 year:2001 number:60 pages:0 |
| sourceStr |
In British journal of dermatology 145(2001), 60, Seite 0 volume:145 year:2001 number:60 pages:0 |
| format_phy_str_mv |
Article |
| institution |
findex.gbv.de |
| topic_facet |
onychomycosis |
| isfreeaccess_bool |
false |
| container_title |
British journal of dermatology |
| authorswithroles_txt_mv |
Baran, R. @@aut@@ |
| publishDateDaySort_date |
2001-01-01T00:00:00Z |
| hierarchy_top_id |
NLEJ24392786X |
| id |
NLEJ242126944 |
| fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">NLEJ242126944</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230505191003.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">120427s2001 xx |||||o 00| ||und c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1111/j.1365-2133.2001.00045.x</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)NLEJ242126944</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Baran, R.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Topical amorolfine for 15 months combined with 12 weeks of oral terbinafine, a cost-effective treatment for onychomycosis[This mater]</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="a">Oxford, UK</subfield><subfield code="b">Blackwell Science Ltd</subfield><subfield code="c">2001</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Objective This open randomized study examined the efficacy of a combination of oral terbinafine and topical amorolfine in the treatment of severe dermatophyte toenail onychomycosis with matrix area involvement. Patients/Methods A total of 147 patients were randomized to one of three treatment groups: 15 months of once-weekly topical amorolfine lacquer in combination with 6 weeks (Group AT6) or 12 weeks (Group AT12) of oral terbinafine, 250 mg once daily; or terbinafine monotherapy for 12 weeks (Group T12). Patients were followed for a total of 18 months. The primary efficacy variable was the result of mycological examination after 3 months of therapy; secondary efficacy variables were mycological and clinical examination at 3-monthly intervals, with an additional clinical evaluation at 18 months. Safety and tolerance were also assessed. Results Negative mycological results, assessed at 3 months, were recorded for 14 of 40 patients (35%) in Group AT6, 11 of 44 (27·5%) in Group AT12 and 7 of 41 (17·1%) in Group T12. At 18 months, the global response (mycological and clinical cure) was seen in 22 of 50 patients (44%), 34 of 47 (72·3%) and 18 of 48 (37·5%) in the AT6, AT12 and T12 groups, respectively. Conclusions These results suggest that a combination therapy regime with oral and systemic treatment is superior in efficacy to monotherapy with a systemic drug alone in the treatment of severe onychomycosis. In addition, the cost per cure ratio was better in the combination groups.</subfield></datafield><datafield tag="533" ind1=" " ind2=" "><subfield code="d">2008</subfield><subfield code="f">Blackwell Publishing Journal Backfiles 1879-2005</subfield><subfield code="7">|2008||||||||||</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">onychomycosis</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">British journal of dermatology</subfield><subfield code="d">Oxford : Wiley-Blackwell, 1892</subfield><subfield code="g">145(2001), 60, Seite 0</subfield><subfield code="h">Online-Ressource</subfield><subfield code="w">(DE-627)NLEJ24392786X</subfield><subfield code="w">(DE-600)2004086-6</subfield><subfield code="x">1365-2133</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:145</subfield><subfield code="g">year:2001</subfield><subfield code="g">number:60</subfield><subfield code="g">pages:0</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">http://dx.doi.org/10.1111/j.1365-2133.2001.00045.x</subfield><subfield code="q">text/html</subfield><subfield code="x">Verlag</subfield><subfield code="z">Deutschlandweit zugänglich</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">ZDB-1-DJB</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_NL_ARTICLE</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">145</subfield><subfield code="j">2001</subfield><subfield code="e">60</subfield><subfield code="h">0</subfield></datafield></record></collection>
|
| series2 |
Blackwell Publishing Journal Backfiles 1879-2005 |
| author |
Baran, R. |
| spellingShingle |
Baran, R. misc onychomycosis Topical amorolfine for 15 months combined with 12 weeks of oral terbinafine, a cost-effective treatment for onychomycosis[This mater] |
| authorStr |
Baran, R. |
| ppnlink_with_tag_str_mv |
@@773@@(DE-627)NLEJ24392786X |
| format |
electronic Article |
| delete_txt_mv |
keep |
| author_role |
aut |
| collection |
NL |
| publishPlace |
Oxford, UK |
| remote_str |
true |
| illustrated |
Not Illustrated |
| issn |
1365-2133 |
| topic_title |
Topical amorolfine for 15 months combined with 12 weeks of oral terbinafine, a cost-effective treatment for onychomycosis[This mater] onychomycosis |
| publisher |
Blackwell Science Ltd |
| publisherStr |
Blackwell Science Ltd |
| topic |
misc onychomycosis |
| topic_unstemmed |
misc onychomycosis |
| topic_browse |
misc onychomycosis |
| format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
| format_main_str_mv |
Text Zeitschrift/Artikel |
| carriertype_str_mv |
zu |
| hierarchy_parent_title |
British journal of dermatology |
| hierarchy_parent_id |
NLEJ24392786X |
| hierarchy_top_title |
British journal of dermatology |
| isfreeaccess_txt |
false |
| familylinks_str_mv |
(DE-627)NLEJ24392786X (DE-600)2004086-6 |
| title |
Topical amorolfine for 15 months combined with 12 weeks of oral terbinafine, a cost-effective treatment for onychomycosis[This mater] |
| ctrlnum |
(DE-627)NLEJ242126944 |
| title_full |
Topical amorolfine for 15 months combined with 12 weeks of oral terbinafine, a cost-effective treatment for onychomycosis[This mater] |
| author_sort |
Baran, R. |
| journal |
British journal of dermatology |
| journalStr |
British journal of dermatology |
| isOA_bool |
false |
| recordtype |
marc |
| publishDateSort |
2001 |
| contenttype_str_mv |
zzz |
| container_start_page |
0 |
| author_browse |
Baran, R. |
| container_volume |
145 |
| physical |
Online-Ressource |
| format_se |
Elektronische Aufsätze |
| author-letter |
Baran, R. |
| doi_str_mv |
10.1111/j.1365-2133.2001.00045.x |
| title_sort |
topical amorolfine for 15 months combined with 12 weeks of oral terbinafine, a cost-effective treatment for onychomycosis[this mater] |
| title_auth |
Topical amorolfine for 15 months combined with 12 weeks of oral terbinafine, a cost-effective treatment for onychomycosis[This mater] |
| abstract |
Objective This open randomized study examined the efficacy of a combination of oral terbinafine and topical amorolfine in the treatment of severe dermatophyte toenail onychomycosis with matrix area involvement. Patients/Methods A total of 147 patients were randomized to one of three treatment groups: 15 months of once-weekly topical amorolfine lacquer in combination with 6 weeks (Group AT6) or 12 weeks (Group AT12) of oral terbinafine, 250 mg once daily; or terbinafine monotherapy for 12 weeks (Group T12). Patients were followed for a total of 18 months. The primary efficacy variable was the result of mycological examination after 3 months of therapy; secondary efficacy variables were mycological and clinical examination at 3-monthly intervals, with an additional clinical evaluation at 18 months. Safety and tolerance were also assessed. Results Negative mycological results, assessed at 3 months, were recorded for 14 of 40 patients (35%) in Group AT6, 11 of 44 (27·5%) in Group AT12 and 7 of 41 (17·1%) in Group T12. At 18 months, the global response (mycological and clinical cure) was seen in 22 of 50 patients (44%), 34 of 47 (72·3%) and 18 of 48 (37·5%) in the AT6, AT12 and T12 groups, respectively. Conclusions These results suggest that a combination therapy regime with oral and systemic treatment is superior in efficacy to monotherapy with a systemic drug alone in the treatment of severe onychomycosis. In addition, the cost per cure ratio was better in the combination groups. |
| abstractGer |
Objective This open randomized study examined the efficacy of a combination of oral terbinafine and topical amorolfine in the treatment of severe dermatophyte toenail onychomycosis with matrix area involvement. Patients/Methods A total of 147 patients were randomized to one of three treatment groups: 15 months of once-weekly topical amorolfine lacquer in combination with 6 weeks (Group AT6) or 12 weeks (Group AT12) of oral terbinafine, 250 mg once daily; or terbinafine monotherapy for 12 weeks (Group T12). Patients were followed for a total of 18 months. The primary efficacy variable was the result of mycological examination after 3 months of therapy; secondary efficacy variables were mycological and clinical examination at 3-monthly intervals, with an additional clinical evaluation at 18 months. Safety and tolerance were also assessed. Results Negative mycological results, assessed at 3 months, were recorded for 14 of 40 patients (35%) in Group AT6, 11 of 44 (27·5%) in Group AT12 and 7 of 41 (17·1%) in Group T12. At 18 months, the global response (mycological and clinical cure) was seen in 22 of 50 patients (44%), 34 of 47 (72·3%) and 18 of 48 (37·5%) in the AT6, AT12 and T12 groups, respectively. Conclusions These results suggest that a combination therapy regime with oral and systemic treatment is superior in efficacy to monotherapy with a systemic drug alone in the treatment of severe onychomycosis. In addition, the cost per cure ratio was better in the combination groups. |
| abstract_unstemmed |
Objective This open randomized study examined the efficacy of a combination of oral terbinafine and topical amorolfine in the treatment of severe dermatophyte toenail onychomycosis with matrix area involvement. Patients/Methods A total of 147 patients were randomized to one of three treatment groups: 15 months of once-weekly topical amorolfine lacquer in combination with 6 weeks (Group AT6) or 12 weeks (Group AT12) of oral terbinafine, 250 mg once daily; or terbinafine monotherapy for 12 weeks (Group T12). Patients were followed for a total of 18 months. The primary efficacy variable was the result of mycological examination after 3 months of therapy; secondary efficacy variables were mycological and clinical examination at 3-monthly intervals, with an additional clinical evaluation at 18 months. Safety and tolerance were also assessed. Results Negative mycological results, assessed at 3 months, were recorded for 14 of 40 patients (35%) in Group AT6, 11 of 44 (27·5%) in Group AT12 and 7 of 41 (17·1%) in Group T12. At 18 months, the global response (mycological and clinical cure) was seen in 22 of 50 patients (44%), 34 of 47 (72·3%) and 18 of 48 (37·5%) in the AT6, AT12 and T12 groups, respectively. Conclusions These results suggest that a combination therapy regime with oral and systemic treatment is superior in efficacy to monotherapy with a systemic drug alone in the treatment of severe onychomycosis. In addition, the cost per cure ratio was better in the combination groups. |
| collection_details |
GBV_USEFLAG_U ZDB-1-DJB GBV_NL_ARTICLE |
| container_issue |
60 |
| title_short |
Topical amorolfine for 15 months combined with 12 weeks of oral terbinafine, a cost-effective treatment for onychomycosis[This mater] |
| url |
http://dx.doi.org/10.1111/j.1365-2133.2001.00045.x |
| remote_bool |
true |
| ppnlink |
NLEJ24392786X |
| mediatype_str_mv |
z |
| isOA_txt |
false |
| hochschulschrift_bool |
false |
| doi_str |
10.1111/j.1365-2133.2001.00045.x |
| up_date |
2024-07-06T00:55:56.023Z |
| _version_ |
1803789120068124672 |
| fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">NLEJ242126944</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230505191003.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">120427s2001 xx |||||o 00| ||und c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1111/j.1365-2133.2001.00045.x</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)NLEJ242126944</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Baran, R.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Topical amorolfine for 15 months combined with 12 weeks of oral terbinafine, a cost-effective treatment for onychomycosis[This mater]</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="a">Oxford, UK</subfield><subfield code="b">Blackwell Science Ltd</subfield><subfield code="c">2001</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Objective This open randomized study examined the efficacy of a combination of oral terbinafine and topical amorolfine in the treatment of severe dermatophyte toenail onychomycosis with matrix area involvement. Patients/Methods A total of 147 patients were randomized to one of three treatment groups: 15 months of once-weekly topical amorolfine lacquer in combination with 6 weeks (Group AT6) or 12 weeks (Group AT12) of oral terbinafine, 250 mg once daily; or terbinafine monotherapy for 12 weeks (Group T12). Patients were followed for a total of 18 months. The primary efficacy variable was the result of mycological examination after 3 months of therapy; secondary efficacy variables were mycological and clinical examination at 3-monthly intervals, with an additional clinical evaluation at 18 months. Safety and tolerance were also assessed. Results Negative mycological results, assessed at 3 months, were recorded for 14 of 40 patients (35%) in Group AT6, 11 of 44 (27·5%) in Group AT12 and 7 of 41 (17·1%) in Group T12. At 18 months, the global response (mycological and clinical cure) was seen in 22 of 50 patients (44%), 34 of 47 (72·3%) and 18 of 48 (37·5%) in the AT6, AT12 and T12 groups, respectively. Conclusions These results suggest that a combination therapy regime with oral and systemic treatment is superior in efficacy to monotherapy with a systemic drug alone in the treatment of severe onychomycosis. In addition, the cost per cure ratio was better in the combination groups.</subfield></datafield><datafield tag="533" ind1=" " ind2=" "><subfield code="d">2008</subfield><subfield code="f">Blackwell Publishing Journal Backfiles 1879-2005</subfield><subfield code="7">|2008||||||||||</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">onychomycosis</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">British journal of dermatology</subfield><subfield code="d">Oxford : Wiley-Blackwell, 1892</subfield><subfield code="g">145(2001), 60, Seite 0</subfield><subfield code="h">Online-Ressource</subfield><subfield code="w">(DE-627)NLEJ24392786X</subfield><subfield code="w">(DE-600)2004086-6</subfield><subfield code="x">1365-2133</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:145</subfield><subfield code="g">year:2001</subfield><subfield code="g">number:60</subfield><subfield code="g">pages:0</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">http://dx.doi.org/10.1111/j.1365-2133.2001.00045.x</subfield><subfield code="q">text/html</subfield><subfield code="x">Verlag</subfield><subfield code="z">Deutschlandweit zugänglich</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">ZDB-1-DJB</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_NL_ARTICLE</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">145</subfield><subfield code="j">2001</subfield><subfield code="e">60</subfield><subfield code="h">0</subfield></datafield></record></collection>
|
| score |
7.399748 |